I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Posterior Uveitis: Understanding and Protecting Your Vision
What Is Posterior Uveitis?
To understand posterior uveitis, it helps to know a little about the structure of the eye and specifically the layer called the uvea.
The uvea is the middle layer of the eye. It has three parts: the iris at the front, the ciliary body in the middle, and the choroid at the back. The choroid is a dense network of blood vessels that supplies oxygen and nutrients to the outer layers of the retina. When the choroid becomes inflamed, this blood supply is disrupted, and the retina can be directly harmed.
Uveitis is named for the part of the eye it affects. Anterior uveitis involves the front of the eye and typically causes redness, pain, and light sensitivity. Posterior uveitis involves the back of the eye. Because the retina and choroid do not contain pain-sensing nerve fibers, inflammation in this area often causes few obvious symptoms early on, making it harder to detect and more likely to cause lasting damage if not found promptly.
Inflammation injures eye tissue in two main ways. In one pathway, inflammatory cells invade the supportive tissue of the choroid, called the stroma. In the other, inflammation targets the choriocapillaris, the fine layer of blood vessels located directly beneath the retina, reducing blood flow to this critical area.
Both processes can break down an important protective structure called the outer blood-retinal barrier, formed by Bruch's membrane and the retinal pigment epithelium, a thin layer of cells that supports the retina. When this barrier fails, fluid can leak beneath the retina. In some cases, abnormal new blood vessels form beneath the retina in a process called choroidal neovascularization, which brings additional risk of vision loss.
Who Gets Posterior Uveitis?
Posterior uveitis can occur at any age, but certain health conditions raise the risk considerably. Understanding the connection between systemic health and eye inflammation is an important part of both diagnosing and managing this condition.
Posterior uveitis is the second most common form of uveitis overall. Uveitis of all types is estimated to account for roughly 10% of blindness in the United States, which underscores how serious untreated inflammation can be. While not every case leads to severe vision loss, the potential consequences make early diagnosis and treatment essential.
People living with certain autoimmune or systemic inflammatory conditions are at higher risk of developing posterior uveitis. Conditions commonly associated with inflammation of the choroid include:
- Sarcoidosis, a disease that causes clusters of inflammatory cells to form in organs including the lungs and eyes
- Behcet disease, a condition involving widespread blood vessel inflammation throughout the body
- Vogt-Koyanagi-Harada (VKH) syndrome, an autoimmune condition that attacks pigmented tissues including the choroid
- Birdshot chorioretinopathy, a chronic inflammatory condition affecting the retina and choroid
- Multifocal choroiditis, which most commonly affects women between the ages of 20 and 60
Infections are among the leading causes of posterior uveitis worldwide. Toxoplasmosis, a parasitic infection, is one of the most common infectious triggers and can produce scarring on the retina that may cause permanent vision loss if not treated. Other infectious causes include herpes viruses, cytomegalovirus (CMV), tuberculosis, and syphilis.
Identifying an infectious cause is critically important because treatment for infectious posterior uveitis is fundamentally different from treatment for non-infectious forms. Starting anti-inflammatory medications without first addressing an active infection can make the condition significantly worse.
A prior episode of uveitis increases the risk of future recurrence. People with weakened immune systems, whether due to medications or underlying medical conditions, are more vulnerable to infectious forms. Certain subtypes of posterior uveitis tend to occur more frequently in particular age groups and demographic populations, and a detailed clinical history helps guide the diagnostic process.
Symptoms of Posterior Uveitis
One of the greatest challenges with posterior uveitis is that its symptoms can be subtle at first. Pain and redness are often absent, which means visual changes are usually the first warning that something is wrong.
Symptoms can develop in one or both eyes and may come on gradually over days or weeks. The most common complaints include:
- Blurry or hazy vision
- Floaters, which appear as spots, strings, or cobweb-like shapes drifting through your field of view
- Blind spots or dark areas within your central or peripheral vision
- Sensitivity to light, also called photophobia
Unlike anterior uveitis, which often causes eye pain and visible redness, posterior uveitis typically does not hurt. The choroid and retina contain no pain-sensing nerve fibers, so inflammation in these tissues may go unnoticed for longer than other eye problems. Some patients notice a mild dull pressure or light sensitivity, but many experience only gradual visual changes. Any unexplained change in vision deserves a prompt evaluation, even without pain or redness.
Certain symptoms may signal a serious complication such as retinal detachment or a sudden severe inflammatory event. Seek immediate care if you experience any of the following:
- A curtain or shadow falling over part of your visual field
- A sudden and significant increase in new floaters
- Flashing lights in your vision
- Sudden or severe loss of vision in one eye
These symptoms should not be monitored at home. Same-day or emergency evaluation by a retina specialist is essential to prevent irreversible damage.
How We Diagnose Posterior Uveitis
Diagnosing posterior uveitis requires more than a standard eye exam. Our specialists use a combination of detailed clinical examination and advanced imaging to identify the location and extent of inflammation and determine its most likely cause.
The evaluation begins with a dilated fundus exam, in which eye drops are used to widen the pupils so the retina specialist can view the retina, choroid, and optic nerve clearly. The specialist looks for signs of inflammation including white or yellow deposits on the choroid or retina, fluid beneath the retina, blood vessel changes, and areas of scarring. Both eyes are examined at every visit, since some forms of posterior uveitis affect both sides even when only one eye seems symptomatic.
Imaging studies provide detailed information about the extent of inflammation and allow us to track how the eye responds to treatment over time. The imaging tools we use include:
- Optical coherence tomography (OCT), which creates high-resolution cross-sectional images of the retina and can detect swelling, fluid, and structural changes in fine detail
- OCT angiography (OCTA), a non-invasive method that maps blood flow in the retinal and choroidal layers without the need for injected dye
- Fluorescein angiography (FA), which uses a dye injected through a vein in the arm to photograph retinal blood vessels and reveal areas of leakage or blockage
- Indocyanine green angiography (ICG), which captures images of the deeper choroidal circulation and is particularly useful for detecting inflammation beneath the retinal pigment epithelium
- Fundus autofluorescence, a non-invasive method that highlights areas of damage to the outer retinal layers
- Wide-field imaging, which captures a broader view of the retina to detect peripheral inflammation that a standard exam might miss
Because posterior uveitis is so frequently linked to a systemic disease or infection, laboratory testing is often a necessary part of the diagnostic process. Blood work can screen for conditions such as sarcoidosis, tuberculosis, syphilis, toxoplasmosis, and various autoimmune markers. In many cases, we coordinate care with a rheumatologist or infectious disease specialist to identify and manage an underlying cause. A complete diagnosis is essential for choosing the right treatment and reducing the risk of recurrence.
Treatment Options for Posterior Uveitis
Treatment depends on whether the inflammation is caused by an infection or by the immune system attacking eye tissue. The approach also depends on the severity of inflammation, whether one or both eyes are affected, and the patient's overall health. The goal is always to control inflammation, protect the retina, and preserve as much vision as possible.
Corticosteroid medications, which reduce inflammation, are a cornerstone of treatment for non-infectious posterior uveitis. For inflammation in the back of the eye, injections placed directly into or near the eye tend to be more effective than eye drops alone. A periocular injection, meaning one placed around rather than inside the eye, can deliver medication to the back of the eye while avoiding some of the risks associated with injections into the vitreous (the gel-filled space inside the eye).
A slow-release dexamethasone implant injected directly into the eye is an FDA-approved option for non-infectious uveitis affecting the posterior segment. It delivers medication gradually over several months. Oral corticosteroids may also be used for severe or bilateral (both eyes affected) disease, though long-term oral use carries systemic side effects that require careful management.
For chronic conditions such as birdshot chorioretinopathy, retinal vasculitis, or multifocal choroiditis, corticosteroid-sparing immunosuppressive medications are typically started early in the course of treatment. These drugs reduce the immune system's ability to drive ongoing inflammation in the eye. They take several months to reach their full effect, so early initiation helps reduce long-term dependence on corticosteroids.
Two commonly used options are methotrexate and mycophenolate mofetil. Clinical research has found both to be similarly effective for achieving steroid-sparing disease control in patients with non-infectious uveitis. These medications require regular blood monitoring to check for potential effects on the liver, kidneys, and blood cell counts.
Adalimumab is currently the only FDA-approved biologic medication for non-infectious posterior and panuveitis. It works by blocking a protein called tumor necrosis factor (TNF), which plays a central role in driving the inflammatory response. This therapy is typically used when other immunosuppressive treatments have not provided adequate disease control or when a patient cannot tolerate them. Treatment decisions involving biologic therapy are always made carefully based on a patient's full medical history and individual circumstances.
When posterior uveitis is caused by an infection, treatment targets the specific organism responsible. Toxoplasmosis is treated with antiparasitic medications. Tuberculosis-related uveitis requires a full course of anti-tuberculosis therapy. Herpes and cytomegalovirus (CMV) infections require antiviral treatment. Addressing the infection is essential before or alongside any anti-inflammatory therapy, since suppressing the immune response without controlling an active infection can allow the organism to spread and cause more damage.
When posterior uveitis leads to choroidal neovascularization, meaning the growth of abnormal new blood vessels beneath the retina, anti-VEGF (vascular endothelial growth factor) injections may be recommended. These medications block the signals that stimulate abnormal vessel growth and fluid leakage. Several anti-VEGF agents are available, and the most appropriate choice depends on the individual patient's clinical situation and the treating physician's assessment.
Complications and Visual Outcomes
Without adequate treatment, posterior uveitis can lead to several serious complications. Understanding what is at stake helps explain why consistent treatment and regular follow-up are not optional but essential.
Poorly controlled posterior uveitis can cause lasting damage to the eye through a number of mechanisms, including:
- Macular edema (swelling in the central retina), which is one of the most common causes of vision loss associated with uveitis
- Choroidal neovascularization, where abnormal blood vessels grow under the retina and may leak fluid or bleed
- Cataracts (clouding of the eye's natural lens), which can result from chronic inflammation or long-term corticosteroid use
- Glaucoma (elevated pressure inside the eye), which can develop as a result of inflammation or as a side effect of steroid treatment
- Retinal scarring, which can cause permanent blind spots that do not recover with treatment
Significant vision loss is a real risk when posterior uveitis is not properly managed. A substantial proportion of patients with posterior uveitis experience measurable declines in visual acuity over time. Outcomes are meaningfully better when inflammation is identified and treated early, before irreversible structural changes such as scarring have developed. Many patients maintain functional vision with appropriate, consistent care.
Even when inflammation appears to be under control, posterior uveitis requires ongoing monitoring. Flare-ups can occur without warning, sometimes months or years after a period of apparent stability. A retina specialist will typically schedule visits every few weeks to every few months depending on disease activity and treatment response. Keeping every appointment, even when your vision feels completely normal, is one of the most important steps you can take to protect your long-term sight.
Living With Posterior Uveitis
Managing posterior uveitis is often a long-term commitment. With the right medical team and consistent habits, most patients can protect their vision and maintain a good quality of life.
Because posterior uveitis is so often connected to a systemic disease, your care may involve more than one type of specialist. A rheumatologist can help manage underlying autoimmune conditions such as sarcoidosis or Behcet disease. An infectious disease specialist may be involved if tuberculosis or another serious infection is identified. Open communication among all your treating providers helps ensure a coordinated approach that addresses both your eye health and your overall health together.
Staying alert to changes in your vision is one of the most valuable things you can do between appointments. New floaters, increased blurriness, or greater light sensitivity may signal a flare-up that needs prompt evaluation. Wearing sunglasses outdoors can help manage light sensitivity during active periods of inflammation. Taking medications exactly as prescribed is critical, particularly immunosuppressive drugs that require consistent dosing to remain effective. Never stop these medications without guidance from your retina specialist, as doing so can trigger a sudden and potentially severe return of inflammation.
Frequently Asked Questions
Here are answers to questions our patients frequently ask about posterior uveitis and what to expect during care.
Yes, and the likelihood depends on the underlying cause. Conditions like Vogt-Koyanagi-Harada syndrome and sarcoidosis frequently involve both eyes simultaneously and may appear nearly identical on both sides. Toxoplasmosis-related uveitis more commonly affects one eye at a time, though the other eye is not entirely protected. This is one reason your retina specialist will examine both eyes at every visit, even when your symptoms seem to involve only one side.
Duration varies considerably based on the underlying cause and how well you respond. Infectious posterior uveitis may resolve once the underlying infection is treated, though your specialist will continue monitoring for possible recurrence. Non-infectious autoimmune-related forms often require months to years of ongoing therapy, and some patients benefit from low-dose maintenance treatment indefinitely to prevent flare-ups. Your treatment plan will be reassessed at regular intervals, and adjustments will be made based on your disease activity and overall health.
Long-term immunosuppressive therapy does carry risks, including a modestly increased susceptibility to infection and potential effects on the liver, kidneys, and blood cell counts. These risks are carefully managed through regular blood monitoring, and dosing is adjusted if problems arise. For most patients with chronic posterior uveitis, the risk of uncontrolled inflammation causing irreversible vision loss is greater than the risk of carefully monitored medication. Your specialist will discuss the specific benefits and risks with you based on your individual circumstances and adjust the plan over time.
Recurrence is common, particularly with autoimmune-related forms. Some patients experience repeated flare-ups over many years, even after long periods of apparent stability. This is why regular monitoring continues even when the eye looks and feels completely normal. Catching a recurrence early, before significant new damage has occurred, allows treatment to begin quickly. It is important to report any new visual symptoms to your retina specialist promptly rather than waiting to see if they resolve on their own.
Posterior uveitis means inflammation is concentrated in the back portion of the uvea, involving the choroid and potentially the retina. Panuveitis means inflammation is present throughout the entire uvea, including the front, middle, and back sections simultaneously. Panuveitis is generally considered more extensive and may require more aggressive treatment. Your retina specialist will determine the correct classification based on where inflammation is present and how widespread it is, which directly shapes the treatment approach.
Expert Posterior Uveitis Care in Connecticut
New England Retina Associates is a retina-only practice with fellowship-trained vitreoretinal surgeons who have extensive experience diagnosing and treating posterior uveitis and the full spectrum of inflammatory retinal conditions. We offer advanced diagnostic imaging, coordinated systemic care, and the most current treatment options available. Whether you have been referred by your ophthalmologist or optometrist, or you are seeking a second opinion, we welcome you to schedule an evaluation at any of our offices throughout Connecticut.
30 Years of Care & Commitment
